CD105 is important for angiogenesis: evidence and potential applications

Angiogenesis is the propelling force for tumor growth and metastasis, and antiangiogenic therapy represents one of the most promising modalities for cancer treatment. CD105 (endoglin) is a proliferation‐associated and hypoxia‐inducible protein abundantly expressed in angiogenic endothelial cells (EC). It is a receptor for transforming growth factor (TGF) ‐β1 and ‐β3 and modulates TGF‐β signaling by interacting with TGF‐β receptors I and/or II. Immunohistochemistry studies have revealed that CD105 is strongly expressed in blood vessels of tumor tissues. Intratumoral microvessel density (MVD) determined using antibodies to CD105 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival. CD105 is able to be shed into the circulation, with elevated levels detected in patients with various types of cancer and positively correlated with tumor metastasis. Tangible evidence of its proangiogenic role comes from knockout studies in which CD105 null mice die in utero as a result of impaired angiogenesis in the yolk sac and heart defects. The potential usefulness of CD105 for tumor imaging has been evaluated in tumor‐bearing mice and dogs that have shown the rapid accumulation of radiolabeled anti‐CD105 monoclonal antibody in the tumors with a high tumor‐to‐background ratio. The anti‐CD105 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppressed/abrogated tumor growth in murine models bearing breast and colon carcinoma without any significant systemic side effects. Immunoscintigraphy in patients with renal cell carcinomas has shown specific localization of 99Tcm‐labeled CD105 mab in tumor endothelial cells. Thus, CD105 is a promising vascular target that can be used for tumor imaging, prognosis, and bears therapeutic potential in patients with solid tumors and other angiogenic diseases.—Duff, S. E., Li, C., Garland, J. M., Kumar, S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17, 984–992 (2003)

[1]  L. Påhlman,et al.  Prognostic significance of the microvascular count in colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Saalmüller,et al.  Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. , 1991, Leukemia.

[3]  A. Srivastava,et al.  The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. , 1988, The American journal of pathology.

[4]  A. Paterson,et al.  Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. , 2001, The American journal of pathology.

[5]  E. Wayner,et al.  Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. , 1997, Tissue antigens.

[6]  J. Martín-Pérez,et al.  Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. , 1994, The Biochemical journal.

[7]  B. Seon.  Expression of endoglin (CD105) in tumor blood vessels , 2002, International journal of cancer.

[8]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[9]  M. Barcos,et al.  Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[11]  D. Ribatti,et al.  Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane , 2005, Clinical Rheumatology.

[12]  B. Bodey,et al.  Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. , 1998, Anticancer research.

[13]  M. Tabata,et al.  Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Folkman.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[15]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[16]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[17]  M. Letarte,et al.  Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. , 1988, Journal of immunology.

[18]  Á. Corbí,et al.  Identification of a Critical Sp1 Site within the Endoglin Promoter and Its Involvement in the Transforming Growth Factor-β Stimulation* , 2001, The Journal of Biological Chemistry.

[19]  J. Wang,et al.  CD 105 and angiogenesis. , 1996, The Journal of pathology.

[20]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[21]  L. Zardi,et al.  Lack of specificity of endoglin expression for tumor blood vessels , 2001, International journal of cancer.

[22]  M. Letarte,et al.  Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. , 1994, Endocrinology.

[23]  D. Nettelbeck,et al.  Cell type specificity of the human endoglin promoter. , 1999, Gene.

[24]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[25]  P. Lastres,et al.  Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. , 1999, European journal of cell biology.

[26]  B. Brooke,et al.  Defective angiogenesis in mice lacking endoglin. , 1999, Science.

[27]  I. Hampson,et al.  CD 105 antagonizes the inhibitory signaling of transforming growth factor b 1 on human vascular endothelial cells , 1999 .

[28]  P. Lastres,et al.  Endoglin modulates cellular responses to TGF-beta 1 , 1996, The Journal of cell biology.

[29]  S. Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[30]  J. Lammers,et al.  Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. , 1996, Archives of internal medicine.

[31]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[32]  C. Cabañas,et al.  Regulated expression on human macrophages of endoglin, an Arg‐Gly‐Asp‐containing surface antigen , 1992, European journal of immunology.

[33]  B. Bodey,et al.  Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. , 1998, Anticancer research.

[34]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[35]  B. Olsen,et al.  Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. , 2002, The Journal of rheumatology.

[36]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Sanchez-Elsner,et al.  Endoglin Expression Is Regulated by Transcriptional Cooperation between the Hypoxia and Transforming Growth Factor-β Pathways* , 2002, The Journal of Biological Chemistry.

[38]  D. Page,et al.  Angiogenesis in human breast carcinoma: what is the question? , 1995, Human pathology.

[39]  N. Pece-Barbara,et al.  Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. , 2000, Human molecular genetics.

[40]  M. Barcos,et al.  Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J. V. van Mourik,et al.  Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.

[42]  R. Hynes,et al.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.

[43]  N. Pece-Barbara,et al.  Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. , 2001, Human molecular genetics.

[44]  M. Letarte,et al.  Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. , 1985, Journal of immunology.

[45]  K. Shyu,et al.  Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. , 2002, Cardiovascular research.

[46]  D. Marchuk,et al.  Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. , 1999, Human molecular genetics.

[47]  M. Letarte,et al.  Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. , 2000, Trends in cardiovascular medicine.

[48]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[49]  P. Adam,et al.  Expression of endoglin mRNA and protein in human vascular smooth muscle cells. , 1998, Biochemical and biophysical research communications.

[50]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[51]  Z. Hall.  Cancer , 1906, The Hospital.

[52]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[53]  T. Sanchez-Elsner,et al.  Extracellular and Cytoplasmic Domains of Endoglin Interact with the Transforming Growth Factor-β Receptors I and II* , 2002, The Journal of Biological Chemistry.

[54]  H. Wada,et al.  Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  Shant Kumar,et al.  Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer , 2000, International journal of cancer.

[56]  M. McAsey,et al.  Endoglin Expression as a Measure of Microvessel Density in Cervical Cancer , 2000, Obstetrics and gynecology.

[57]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[58]  D. Dumont,et al.  A murine model of hereditary hemorrhagic telangiectasia. , 1999, The Journal of clinical investigation.

[59]  B. Seon,et al.  Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.

[60]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[61]  R. Brekken,et al.  Strategies for vascular targeting in tumors , 2002, International journal of cancer.

[62]  J. Massagué,et al.  Identification and expression of two forms of the human transforming growth factor‐β‐binding protein endoglin with distinct cytoplasmic regions , 1993, European journal of immunology.

[63]  M. Tabata,et al.  Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I‐labeled anti‐endoglin monoclonal antibodies , 1999, International journal of cancer.

[64]  A. Freemont,et al.  Mast cells in the pathogenesis of chronic back pain: a hypothesis , 2002, The Journal of pathology.

[65]  L. Attisano,et al.  Role of Endoglin in Cellular Responses to Transforming Growth Factor-β , 1998, The Journal of Biological Chemistry.

[66]  P. V. D. van de Kerkhof,et al.  Expression of endoglin in the transition between psoriatic uninvolved and involved skin. , 1998, Acta dermato-venereologica.

[67]  J. Wrana,et al.  Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β Superfamily* , 1999, The Journal of Biological Chemistry.

[68]  M. Maio,et al.  Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  M. Letarte,et al.  Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. , 1988, Journal of immunology.

[70]  N. Kay,et al.  B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.

[71]  Robertson Rp.  Seminars in medicine of the Beth Israel Hospital, Boston: Pancreatic and islet transplantation for diabetes--cures or curiosities? , 1992 .

[72]  N. Tanigawa,et al.  Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas. , 1997, British Journal of Cancer.

[73]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[74]  Y. Kimura,et al.  Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. , 2002, Surgery.

[75]  C. Shovlin.  Molecular Defects in Rare Bleeding Disorders: Hereditary Haemorrhagic Telangiectasia , 1997, Thrombosis and Haemostasis.

[76]  A. Ramaswamy,et al.  Elevated expression of endoglin, a component of the TGF‐β‐receptor complex, correlates with proliferation of tumor endothelial cells , 1999, International journal of cancer.

[77]  Joshua R. Smith,et al.  Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. , 1998, Blood.

[78]  D. Marchuk,et al.  Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. , 2000, Developmental biology.

[79]  P. Stattin,et al.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer , 2002, The Prostate.

[80]  S. Kumar,et al.  Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. , 1994, Journal of the National Cancer Institute.

[81]  Logtenberg,et al.  New strategies in anti‐vascular cancer therapy , 1999, European journal of clinical investigation.

[82]  T. Bellón,et al.  Assignment of the human endoglin gene (END) to 9q34-->qter. , 1993, Cytogenetics and cell genetics.